An agreement between two companies to invest in R&D, production and commercialisation of new products, is flourishing nearly 3 years after their initial meeting.
First brought together by Enterprise Europe Network team at RTC North in 2013, ImmonoSYS based in Manchester has been working with Dutch company Abunduz to produce and commercialise technology in therapeutic protein development.
Production and commercialisation of new products.
After the initial meeting facilitated by Leo Donato, RTC North, the companies composed a memorandum of understanding detailing a cooperation strategy based on:
Now, nearly 3 years after their initial meeting, the companies are considering merging and creating a new company based in the UK.
ImmunoSYS provides solutions to biological businesses through academia-to-industry translation of bioscience, with particular focus on immunology, proteins, probiotics and biomarkers.
Abundnz specialise in the development of innovative approaches and technologies in the biotechnology and diagnostics industries.